--- title: "Clinical AI Trials Outlive the Models They Evaluate" slug: "healthcare-ai-validation-paradox-model-cycle-vs-clinical-trials" author: "Blanca Amigot" date: "2026-09-19 13:00:00" category: "Premium" topics: "clinical AI, AI validation, model evaluation, FDA PCCP, healthcare AI, model-agnostic architecture, clinical trials" summary: "Claude Opus 4.1 was retired on 5 August 2026, a year after release, while a 2013 PLOS Medicine study of 600 trials found a median of 21 months from trial completion to publication — and only 19.4% of completed AI imaging trials publish at all." banner: "" thumbnail: "" linkedin: | Claude Opus 4.1 was retired on 5 August 2026, one year to the day after its release. Hold that next to how clinical evidence moves. A 2013 PLOS Medicine study of 600 trials with results posted on ClinicalTrials.gov found a median of 21 months from trial completion to journal publication — and about half of those trials had no journal publication at all. In AI medical imaging it is starker. A September 2026 analysis in Academic Radiology found peer-reviewed publication for 79 of 408 completed trials: 19.4%. So the familiar line — that models change every six months while validation takes two to three years — misses on both halves. The model cadence is faster than six months: Anthropic shipped five Opus-class models between 24 November 2025 and 24 July 2026, and OpenAI followed GPT-5.6 in July 2026 with GPT-6 Astra on 4 September 2026. And the validation problem is not mainly slowness, it is that four in five completed studies never report. What that means for a health system is specific: → The model version named in a published study may no longer be callable at all, not merely superseded → Evidence generated once, externally, expires on a vendor's release schedule → The FDA already conceded the point: its December 2024 final guidance lets manufacturers pre-authorize model changes under a predetermined change control plan → The durable asset is the evaluation harness — your labeled cases, your thresholds, your provenance — not any one model With ibl.ai you own all the code and the data — self-hosted inside your own perimeter, model-agnostic across any LLM, usage-based with no per-seat pricing, deployable anywhere from your own cloud to a fully air-gapped network. #iblai #AgenticAI #EnterpriseAI #HealthcareAI #ClinicalAI #AIGovernance --- ## The Short Answer **Frontier models turn over in weeks, not years: five Opus-class Claude models shipped between 24 November 2025 and 24 July 2026, and Claude Opus 4.1 was retired on 5 August 2026, one year after release. A 2013 PLOS Medicine study of 600 trials found a median of 21 months from trial completion to publication. With ibl.ai you own all the code and the data, so the evaluation harness, not any one model, is the asset that survives.** The mismatch is real. The usual framing of it is wrong in both directions, and the correction changes what a health system should build. ## How often do frontier AI models actually change? Faster than the familiar "every six months," and the published lifecycle dates settle it. Anthropic shipped five Opus-class models inside eight months: [Claude Opus 4.5 on 24 November 2025, 4.6 on 5 February 2026, 4.7 on 16 April 2026, 4.8 on 28 May 2026 and Claude Opus 5 on 24 July 2026](https://en.wikipedia.org/wiki/Claude_%28language_model%29). That is a new flagship roughly every eight to ten weeks, and it excludes the Sonnet, Haiku, Fable and Mythos lines released alongside them. OpenAI's cadence is comparable: [GPT-5.6 went to limited preview on 26 June 2026 and to public release on 9 July 2026](https://en.wikipedia.org/wiki/GPT-5.6), and [GPT-6 Astra followed on 4 September 2026](https://www.aljazeera.com/economy/2026/9/4/openai-unveils-gpt-6-astra-amid-rising-scrutiny-and-safety), two months later. ## Does a model named in a clinical study still exist when the study publishes? Often it does not — and this is stronger than "superseded," because the endpoint stops answering. Anthropic's [model deprecation page](https://platform.claude.com/docs/en/about-claude/model-deprecations) records the dates. `claude-opus-4-1-20250805` was deprecated on 5 June 2026 and **retired on 5 August 2026**, one year to the day after its snapshot date. `claude-opus-4-20250514` and `claude-sonnet-4-20250514` were retired on 15 June 2026. `claude-3-7-sonnet-20250219` was retired on 19 February 2026. Requests to a retired model fail. A protocol that pinned one of those identifiers for reproducibility cannot be re-run, and a reader cannot check the result against the artifact that produced it. That is a different problem from a model getting better. It is the evaluated system ceasing to be available, on a schedule the institution does not control. ## How long does clinical validation of an AI system actually take? Long, but the more useful number is not duration — it is how often validation reports at all. A 2013 PLOS Medicine study of 600 trials with results posted on ClinicalTrials.gov found a [median of 21 months from trial completion to journal publication](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001566), interquartile range 14 to 28 months. That clock starts after the trial has already run. In the same sample, about half of the trials with posted results had no corresponding journal publication. AI-specific evidence is thinner still. A September 2026 analysis in *Academic Radiology* assembled 408 registered AI medical-imaging trials with primary completion on or before 1 May 2023 and searched for publications as of 1 May 2026. It [identified peer-reviewed publication for 79 of them — 19.4%](https://pubmed.ncbi.nlm.nih.gov/42431797/). Observational design, inclusion of children and smaller planned enrollment predicted lower publication likelihood. So "validation takes two to three years" understates it. Three years after completion, four in five completed AI imaging trials had produced no published result — not late evidence, no evidence. ## What does the FDA say about AI models that change after authorization? It stopped requiring the model to hold still, which is the regulatory acknowledgment of exactly this paradox. In December 2024 the FDA finalized [Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions](https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-software-medical-device). A PCCP is reviewed as part of the original marketing submission and describes planned modifications, the methodology used to develop and validate them, and an impact assessment. Modifications covered by the plan can then be implemented without a new marketing submission. The shift is from validating an artifact to authorizing a **process** for changing one. Unlike the draft, the final guidance applies to all AI-enabled device software functions, not just machine-learning ones. For a health system the implication is direct: the reviewable object is the change-control and re-evaluation machinery, and that machinery has to be something you operate rather than something a vendor reports on. ## What is the durable asset in clinical AI if it is not the model? The evaluation harness — the labeled cases, the thresholds, the provenance records and the re-run discipline that outlive every model in it. Concretely, four things are worth owning because they do not expire when a checkpoint does. - **Your own labeled case set**, drawn from your adjudicated records and labeled by the clinicians who do the work — not a public benchmark. - **Thresholds tied to your case mix**, so a model swap is judged on your population rather than on a leaderboard. - **Provenance on every output**: which model identifier, which prompt version, which retrieved documents, retained long enough to reconstruct a decision. - **A promotion gate**, so a new model reaches clinical use only after the suite re-runs and clears. The Beijing AI-TEC deployment shows why the harness has to sit where the work happens: use of the agents went from [3.8% of examinations to 23%](/blog/nature-medicine-beijing-eye-clinic-agent-deployment-environment) after workflow changes, with no change to the models. It is the same discipline as treating [evaluation rather than generation as the enterprise problem](/blog/jev-judge-model-evaluation-not-generation-enterprise), and the same reason [healthcare AI pilots fail on architecture rather than model quality](/blog/healthcare-ai-pocs-fail-architecture-not-model). ## How does ibl.ai keep clinical AI validation from expiring? By making the evaluation machinery an artifact the institution holds, and the model a replaceable dependency underneath it. With ibl.ai you own all the code and the data. The platform runs on your own infrastructure under a full source-code license, so the evaluation suites ship as code in your repository and run in your CI, against your data, on your schedule. Every response records the sources used, the policy in force and the pinned model checkpoint that produced it. It is model-agnostic across any LLM, so a retired checkpoint is a dependency swap rather than a re-platforming: when a stronger model ships, it is re-based and the suite re-runs before anything is promoted. The [platform's model catalogue auto-syncs behind a verification gate](/updates/platform-update-2026-09-18) that tests multi-turn recall, streaming, tool calling, image input and a real, non-zero cost before a discovered model is activated. Billing is usage-based with no per-seat pricing, and you deploy anywhere — your own cloud, on-premise, GovCloud or a fully air-gapped network — so protected health information never crosses a boundary you do not control. 1.6M+ users across 400+ organizations run the platform this way, including NVIDIA, MIT, and Syracuse University. For health systems this is the difference between evidence you rent and evidence you keep. [Agentic OS](/product/agentic-os) is the same stack our [healthcare deployments](/solutions/medical-healthcare) run on. ibl.ai is family-owned and operated from New York, NY. *Related reading: [most healthcare AI pilots never reach production](/blog/healthcare-ai-pocs-fail-architecture-not-model) — the architecture that decides whether a validated system ships at all, and [Beijing's AI eye clinic at 3.8% clinician adoption](/blog/nature-medicine-beijing-eye-clinic-agent-deployment-environment).* *Sources: Claude model release dates from [Wikipedia's Claude model list](https://en.wikipedia.org/wiki/Claude_%28language_model%29) and retirement dates from [Anthropic's model deprecation page](https://platform.claude.com/docs/en/about-claude/model-deprecations); GPT-5.6 dates from [its Wikipedia entry](https://en.wikipedia.org/wiki/GPT-5.6) and the GPT-6 Astra date from [Al Jazeera](https://www.aljazeera.com/economy/2026/9/4/openai-unveils-gpt-6-astra-amid-rising-scrutiny-and-safety); the 21-month median from [Riveros et al., PLOS Medicine, 2013](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001566); the 19.4% publication yield from [Academic Radiology, September 2026](https://pubmed.ncbi.nlm.nih.gov/42431797/); the PCCP final guidance from [FDA](https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-software-medical-device).* ## Why does owning the AI stack matter? **ibl.ai is the agentic AI platform where you own all the code and the data. You self-host the entire stack inside your own perimeter, run it model-agnostic across any LLM and switch anytime, and pay by usage with no per-seat pricing — so you can deploy anywhere: your cloud, on-premise, GovCloud, or fully air-gapped.** - **You own all the code and the data.** Full source code under a perpetual license, running on your infrastructure. Not API access to someone else's platform — the stack itself is yours. - **Model-agnostic.** Run any LLM — Claude, GPT, Gemini, Llama, Command, or your own fine-tune — and switch providers without rewriting the platform. - **No per-seat pricing.** Usage-based billing against a budget cap you set. Cost tracks what your organization actually uses, not how many people you employ. - **Deploy anywhere.** Your cloud, your VPC, on-premise, GovCloud, or a fully air-gapped network with no outbound connectivity. 1.6M+ users across 400+ organizations run the platform this way, including NVIDIA, MIT, and Syracuse University. ibl.ai is family-owned and operated from New York, NY — a U.S.-headquartered, domestically-owned long-term partner, not a vendor that sells licenses and moves on.